GW-501516 (Cardarine) | 10mg/mL $40.99 Batch and lot coded with publicly visible lab reports to ensure quality and transparency
& Munoz, M
Disclosures: David Goldberg: Nothing to Disclose, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Binu John: Exact Sciences: Grant/Research Support, Genentech: Grant/Research Support, Glycotest, Inc: Grant/Research Support, Gilead: Grant/Research Support, Exelixis: Consultant, Takeda: Grant/Research Support, GlaxoSmithKline: Consultant, Astra Zeneca: Consultant, Neelima Gaddipati: Nothing to Disclose, Sirisha Gaddipati: Nothing to Disclose, Yalda Zarnegarnia: Nothing to Disclose, Peter Reese: Nothing to Disclose, Catherine Blandon: Bluebird Bio: Stock - publicly traded company, Intellia Therapeutics: Stock - publicly traded company, Editas Medicine: Stock - publicly traded company 2640 THREE-DIMENSIONAL MR ELASTOGRAPHY PREDICTS CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH CIRRHOSIS: A PROSPECTIVE MULTICENTER STUDY Yu Shi 1 He Zhu 2 Meng Niu 1 Jie Chen 3 Bo Wei 3 Bin Song 3 Zhenghan Yang 4 Hui Xu 4 Dawei Yang 4 Jingjing Liu 5 Yong Zhang 5 Jingliang Cheng 5 Xiaolong Qi 6 , 1 China Medical University, 2 The Sixth Peoples Hospital of Shenyang, 3 Sichuan University West China Hospital, 4 Beijing Friendship Hospital, 5 First Hospital of Zhengzhou University, 6 Zhongda Hospital, Southeast University Background: To explore a Three-dimensional MR elastography (3D-MRE) model for noninvasive diagnosis of clinically significant portal hypertension (CSPH, HVPG10mmHg) and severe portal hypertension (SPH, HVPG12mmHg) in cirrhosis, using hepatic venous pressure gradient (HVPG) as the gold standard
M.VidaurreD.BeckmannC
